Related Experiment Video

Updated: Jun 16, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

EGFR signaling and drug discovery

Georg Lurje1, Heinz-Josef Lenz

  • 1Department of Visceral- and Transplantation Surgery, University Hospital Zurich, Zurich, Switzerland.

Oncology
|February 5, 2010
PubMed

Insights

Dysregulation of human epidermal growth factor receptor (ErbB/HER) pathways drives cancer progression. Targeted therapies like monoclonal antibodies and tyrosine kinase inhibitors show promise in blocking tumor growth and are approved for various cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Dysregulation of human epidermal growth factor receptor (ErbB/HER) pathways, through overexpression or constitutive activation, contributes to tumor progression, including angiogenesis and metastasis, correlating with poor prognosis in malignancies.
  • ErbB signaling is implicated not only in cancer but also in cardiovascular and neurodegenerative diseases.

Purpose of the Study:

  • To review the role of ErbB pathways in cancer and the therapeutic potential of targeted inhibitors.
  • To highlight approved anti-ErbB therapies and their clinical applications.

Main Methods:

  • Review of scientific literature on ErbB pathway dysregulation and targeted therapies.
  • Analysis of preclinical data (in vitro and xenograft models) and clinical outcomes of approved anti-ErbB agents.

Main Results:

  • Inhibition of ErbB pathways using monoclonal antibodies (MoAbs) or tyrosine kinase inhibitors (TKIs) effectively blocks cell cycle progression, reduces pro-angiogenic factors, and induces apoptosis in various cancer models.
  • Several anti-ErbB MoAbs and TKIs are approved for treating advanced colorectal cancer, head and neck squamous cell carcinoma, non-small-cell lung cancer, pancreatic cancer, and breast cancer.

Conclusions:

  • The ErbB receptor family, particularly EGFR and HER-2, are validated therapeutic targets for anti-cancer strategies.
  • Targeted ErbB-directed therapies have demonstrated significant clinical efficacy, although further research is warranted.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...